Report of the Post Kala-Azar Dermal Leishmaniasis (PKDL) consortium meeting, New Delhi, India, 27–29 June 2012

Particle and Fibre Toxicology

Ed E Zijlstra¹  Nathalie Strub-Wourgaft¹  Pritu Dhalaria²  Raj Shankar Ghosh²  Philippe Desjeux² 

[1]DNDi, 15 Chemin Louis Dunant, Geneva 1202, Switzerland

[2]PATH OWH, A-9, Qutub Institutional area, USO Road, New Delhi 110067, India

关键词: Visceral leishmaniasis;    Post kala-azar dermal leishmaniasis;    PKDL;    Consortium report;   

Others  :  1226168
DOI  :  10.1186/1756-3305-6-196

 received in 2013-04-02, accepted in 2013-05-17,  发布年份 2013

【 摘 要 】

Post kala-azar dermal leishmaniasis (PKDL) is a neglected complication of visceral leishmaniasis (VL)―a deadly, infectious disease that claims approximately 20,000 to 40,000 lives every year. PKDL is thought to be a reservoir for transmission of VL, thus, adequate control of PKDL plays a key role in the ongoing effort to eliminate VL. Over the past few years, several expert meetings have recommended that a greater focus on PKDL was needed, especially in South Asia. This report summarizes the Post Kala-Azar Dermal Leishmaniasis Consortium Meeting held in New Delhi, India, 27–29 June 2012. The PKDL Consortium is committed to promote and facilitate activities that lead to better understanding of all aspects of PKDL that are needed for improved clinical management and to achieve control of PKDL and VL. Fifty clinicians, scientists, policy makers, and advocates came together to discuss issues relating to PKDL epidemiology, diagnosis, pathogenesis, clinical presentation, treatment, and control. Colleagues who were unable to attend participated during drafting of the consortium meeting report.

【 授权许可】

   
2013 Desjeux et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M: WHO Leishmaniasis Control Team: Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7:e35671.
• [2]Thakur CP, Kumar K: Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann Trop Med Parasitol 1992, 4:355-359.
• [3]Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, Bhattacharya SK, Sinha A: Impact of amphotericin B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res 2008, 128:38-44.
• [4]Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK, Kumar A: Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 1997, 91:611-616.
• [5]Sen Gupta PC: Leishmaniasis in India. J Ind Med Assoc 1968, 50:34-36.
• [6]Brahmachari UN: A new form of cutaneous leishmaniasis dermal leishmanoid. Indian Med Gaz. 1922, 57:125.
• [7]Agarwal A, Sinha A, Rizal A, Rizal S: Post kala-azar dermal leishmaniasis in eastern Nepal [Abstract]. In 13th International Congress on Oral Pathology and Medicine. Brisbane, Australia; 2006. http://www.icms.com.au/iaop2006/abstract/23.htm webcite
• [8]Garg VK, Agrawal S, Rani S, Joshi A, Agarwalla A, Das ML, Koirala S: Post-kala-azar dermal leishmaniasis in Nepal. Int J Derm 2001, 40:179-184.
• [9]Uranw S, Ostyn B, Rijal A, Devkota S, Khanal B, Menten J, Boelaert M, Rijal S: Post kala-azar dermal leishmaniasis in Nepal: a retrospective cohort (2000–2010). PLoS Negl Trop Dis 2011, 5:e1433.
• [10]Zijlstra EE, El-Hassan AM: Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. Trans Roy Soc Trop Med Hyg 2001, 95:S164-S176.
• [11]El-Hassan AM, Ghalib HW, Zijlstra EE, Eltoum IA, Satti M, Ali MS, Ali HM: Post kala azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. Trans Roy Soc Trop Med Hyg 1992, 86:245-248.
• [12]El-Hassan AM, Ghalib HW, Zijlstra EE, Eltoum IA, Ali MS, Ahmed HM: Post kala azar dermal leishmaniasis in the absence of active visceral leishmaniasis. Lancet 1990, 336:750.
• [13]Zijlstra EE, El-Hassan AM, Ismael A, Ghalib HW: Endemic kala-azar in eastern Sudan : a longitudinal study on the incidence of clinical and subclinical infection and post kala-azar dermal leishmaniasis. AmJTrop Med Hyg 1994, 51:826-836.
• [14]Zijlstra EE, Khalil EA, Kager PA, El Hassan AM: Post kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 2000, 143:136-143.
• [15]Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El-Hassan AM: Post kala-azar dermal leishmaniasis. Lancet Infect Dis 2003, 3:87-97.
• [16]Addy M, Nandy A: Ten years of kala-azar in West Bengal, part 1. Did post kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Org 1992, 70:341-346.
• [17]Kirk R, Lewis DJ: Studies in leishmaniasis in the Anglo-Egyptian Sudan. XI. Phlebotomus in relation to leishmaniasis in the Sudan. Trans R Soc Trop Med Hyg 1955, 49:229-240.
• [18]El Hassan AM, Khalil EAG: Post kala-azar dermal leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan? Trop Med Int Health 2001, 6:743-744.
• [19]Mondal D, Khan MG: Recent advances in post-kala-azar dermal leishmaniasis. Curr Opin Infect Dis 2011, 24:418-422.
• [20]Noiri E, Hamasaki Y, Negishi K, Sugaya T, Doi K, Fujita T, Osada Y, Matsumoto Y, Jamil K: The potential of urinary tests in the management of kala-azar. In Kala-azar in South-Asia. Edited by Jha TK, Noiri E. New York, US: Springer-Verlag; 2011:69-90.
• [21]Salotra P, Sreenivas G, Ansari NA, Subba Raju BV, Ramesh V: Evaluation of enzyme-linked immunosorbent assay for diagnosis of post-kala-azar dermal leishmaniasis with crude or recombinant rK39 antigen. Clin Diagn Lab Immunol 2002, 9:370-373.
• [22]Salotra P, Sreenivas G, Pogue GP, Lee N, Nakhasi HL, Ramesh V, Negi NS: Development of species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post kala-azar dermal leishmaniasis. J Clin Microbiol 2001, 39:849-854.
• [23]Salotra P, Sreenivas G, Beena KR, Mukherjee A, Ramesh V: Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods. J Clin Pathol 2003, 56:840-843.
• [24]Salotra P, Singh R: Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res 2006, 123:295-310.
• [25]Musa AM, Khalil EA, Raheem MA, Zijlstra EE, Ibrahim ME, Elhassan IM, Mukhtar MM, El Hassan AM: The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol 2002, 96:765-772.
• [26]Matsumoto Y, Sanjoba C, Asada M, Osada Y, Matsumoto Y: Polymorphism of leishmaniasis caused by Leishmania donovani Sensu Lato in Asia. In Kala-azar in South-Asia. Edited by Jha TK, Noiri E. New York, US: Springer-Verlag; 2011:101-110.
• [27]Gasim S, Elhassan AM, Kharazmi A, Khalil EA, Ismail A, Theander TG: The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 2000, 119:523-529.
• [28]Gupta S, Raychaudhury B, Datta SC: Host peroxisomal properties are not restored to normal after treatment of visceral leishmaniasis with sodium antimony gluconate. Exp Parasitol 2009, 123:140-145.
• [29]Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N: IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 2007, 179:5592-5603.
• [30]Ramesh V, Ramam M, Singh R, Salotra P: Hypopigmented post kala-azar dermal leishmaniasis. Int J Dermatol 2008, 47:414-416.
• [31]Ramesh V, Singh N: A clinical and histopathological study of macular type of post kala-azar dermal leishmaniasis. Trop Doct 1999, 29:205-207.
• [32]Rahman KM, Islam S, Rahman MW, Kenah E, Ghalib CM, Zahid MM, Maguire J, Rahman M, Haque R, Luby SP, Bern C: Increasing incidence of post kala-azar dermal leishmaniasis in a population-based study in Bangladesh. Clin Infect Dis 2010, 50:73-76.
• [33]Rahman R, Bangali M, Kabir H, Naher FB, Mahboob S: Kala-azar situation in Bangladesh. In National Guideline and Training Module for Kala-azar Elimination in Bangladesh. Edited by Hossain M. Bangladesh; 2008:11-12. CDC, DGHS, Ministry of Health and Family Welfare, Government of the Peoples Republic of Bangladesh
• [34]Ramesh V, Kumar J, Kumar D, Salotra P: A retrospective study of intravenous sodium antimony gluconate alone and in combinations with, allopurinol, rifampicin and an immunomodulator in the treatment of Indian post- kala-azar dermal leishmaniasis. Ind J Dermatol Venereol Leprol 2010, 76:138-144.
• [35]Ramesh V, Katara GK, Verma S, Salotra P: Miltefosine as an effective choice in the treatment of post kala-azar dermal leishmaniasis. Br J Dermatol 2011, 165:411-414.
• [36]Ramesh V, Ansari NA, Jain RK, Salotra P: Oral miltefosine in the treatment of post kala-azar dermal leishmaniasis. Clin Exp Dermatol 2007, 33:103-105.
• [37]Musa AM, Khalil EA, Mahgoug FA, Hamad S, Elkadaru AM, El Hassan AM: Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol 2005, 99:563-569.
• [38]Musa AM, Khalil GAE, Mahgoub EAF, Elgawi SH, Modabber F, Elkadaru AE, Aboud MH, Noazin S, Ghalib HW, El-Hassan AM, Leishmaniasis Research Group/Sudan: Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans Roy Soc Trop Med Hyg 2008, 102:58-63.
• [39]Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN: Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001, 95:668-672.
• [40]Dejenie Belay A, Asafa Y, Mesyre J, Davidson RN: Successful miltefosine treatment of post kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Ann Trop Med Parasitol 2006, 3:223-227.
• [41]Modabber F: Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 2010, 36(Suppl 1):S58-S61.
• [42]Mondal D, Khan GM: Recent advances in post kala-azar dermal leishmaniasis. Curr Opin Infect Dis 2011, 24:418-422.
• [43]Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, Thomas T, Haque R: Enhanced case detection and improved diagnosis of PKDL in a kala-azar endemic area of Bangladesh. PLoS Negl Trop Dis 2010, 4:e832.
• [44]Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddhivinayak H, Kroeger A, Boelaert M: Visceral leishmaniasis elimination program in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009, 3:e355.
• [45]Desjeux P, Ramesh V: Post kala-azar dermal leishmaniasis (PKDL): facing the challenge of eliminating kala-azar from South Asia. In Kala-azar in South-Asia. Edited by Jha TK, Noiri E. New York, US: Springer-Verlag; 2011:111-124.
• [46]Dye C, Wolpert DM: Earthquakes, influenza and cycles of Indian kala-azar. Trans R Soc Trop Med Hyg 1988, 82:843-850.